NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
(Total Views: 203)
Posted On: 02/12/2019 3:46:06 PM
NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Appoints New Member to Board of Directors
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced the appointment of Jamieson Bondarenko, CFA, CMT, to the company’s Board of Directors. Through his merchant capital company, JGRNT Capital Corp., Bondarenko currently offers strategic capital markets and corporate development advice to early-stage life sciences companies. He has also served as Principal, Managing Director of Equity Capital Markets at Eight Capital and Equity Capital Markets as well as Investment Banking positions at Dundee Capital Markets, Wellington West Capital Markets and HSBC Securities. “Jamieson brings extensive capital markets experience to BriaCell,” BriaCell Chairman Dr. Saeid Babaei stated in the news release. “His expertise will be a valuable resource for BriaCell in the current investment environment as we execute our mission to bring innovative therapeutics to patients who tirelessly fight the deadliest forms of advanced breast cancer with no effective treatment options.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced the appointment of Jamieson Bondarenko, CFA, CMT, to the company’s Board of Directors. Through his merchant capital company, JGRNT Capital Corp., Bondarenko currently offers strategic capital markets and corporate development advice to early-stage life sciences companies. He has also served as Principal, Managing Director of Equity Capital Markets at Eight Capital and Equity Capital Markets as well as Investment Banking positions at Dundee Capital Markets, Wellington West Capital Markets and HSBC Securities. “Jamieson brings extensive capital markets experience to BriaCell,” BriaCell Chairman Dr. Saeid Babaei stated in the news release. “His expertise will be a valuable resource for BriaCell in the current investment environment as we execute our mission to bring innovative therapeutics to patients who tirelessly fight the deadliest forms of advanced breast cancer with no effective treatment options.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)